Valion Bio, Inc. — Form 8-K
Filed October 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On October 7, 2026, Valion Bio closed a transaction with 3i, LP for $50,000 in immediate capital. 3i purchased 50 Series B Preferred Shares and warrants to buy 1,539 common shares at $2.5520/share. This represents a partial closing under a larger Series B framework (up to $8.4M total) and follows 3i's prior $13.637M Series C investment in December 2025.
Why this rating
At $4M market cap, $50K is 1.25% of company value—routine capital draw. Consistent with prior financing; no strategic shift signaled.
See more from October 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.